A Clinical Gene Therapy Study with Hematopoietic Stem Cells for the Treatment, with Single Dose of Temferon, of Patients with Metastatic Renal Cell Carcinoma | ClinicalTrials.gov @GenentaScience @MyUniSR @SanRaffaeleMI clinicaltrials.gov/study/NCT06716…
Andrea Necchi
2,934 posts
Associate Professor @MyUniSR - Director of Genitourinary Medical Oncology @SanRaffaeleMI - Vice President @GTumors - Associate Editor @JCO_ASCO
Milano
Joined April 2012
- The new ICU @SanRaffaeleMI realized in 2 weeks is almost ready for the fight against #coronavirus This is the 🇮🇹spirit, not the songs at the balcony
- 3-y FUP update of #PURE01. RFS/EFS confirm early positive data, w potential benefit across ypTN categories. @BasileG_ @BandiniMd @MyUniSR @SanRaffaeleMI aacrjournals.org/clincancerres/…
- Profoundly honored to serve as new Associate Editor @JCO_ASCO continuing the path of Mike Carducci | a special thank to the EiC @DrJFriedberg and the exceptional editorial staff @ASCO @MyUniSR @SanRaffaeleMI
- My take on #VESPER study: 🍸ddMVAC confirms to be a very cool regimen used in referral centers (including mine). Congrats to authors! 🫙N. cycles of chemo needed to cure pts remains unknown 🍼translation in real world remains challenging 🧃Validity of conclusion slide uncertain
- Incredibly honored and humbled to receive today the “Beppe Della Porta” award by @AIRC_it from the hands of our President Sergio Mattarella @Quirinale in recognition of the huge work of my entire team @SanRaffaeleMI @MyUniSR @RaiUno @ElisirTv
- I am pleased to share our last platinum priority paper from collaborative work: Molecular Characterization of Residual Bladder Cancer after Neoadj Pembrolizumab @ewanagibb @JoepJdeJong @pcvblack @Roland3097 @DanieleRaggi83 @LauraLmar89 #PURE01 @EUplatinum europeanurology.com/article/S0302-…
- Meaningful new data published today in MIBC. It becomes clear that validating the role of pCR as surrogate biomarker of OS/EFS after checkpoint inhibition alone is primarily needed @sonpavde @drenriquegrande @ewanagibb @shilpaonc @urotoday @BandiniMd @SanRaffaeleMI @MyUniSR
- Stay tuned on Monday June 2 Hall C 10.15-11.15AM | How to become a successful author @JCO_ASCO @ASCO #ASCO25 #CareerDevelopment #PublicationLounge cdn.bfldr.com/KOIHB2Q3/as/7c…
- Exploratory biomarker analyses of adjuvant #nivolumab in urothelial carcinoma from #CheckMate274 trial are out in @NatureMedicine @MattGalsky | 1. Pre-existing immune infiltration and T-cell infiltration is prognostic and predictive of adj Nivo benefit 2. Composite model
- The PARP inhibitors story and companion bmks in advanced #bladdercancer warrants additional chapters. Great efforts and studies presented at #GU22, several questions remain open to debate @SanRaffaeleMI @SanRaffaeleMI @urotoday @GTumors @MassimoDiMaio75 @DrRosenbergMSK S. Crabb
- Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies europeanurology.com/article/S0302-…
- @NCCN #bladdercancer Guidelines 2024 now include pembrolizumab as a therapeutic option for pts with BCG-unresponsive Ta/T1 papillary tumors without Tis. Based on the results of Keynote-057 Cohort-B trial @CMercinelli @vale_tateo @Anto_cigliola @urotoday @UroDocAsh @PGrivasMDPhD
















